Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Previous issues

Page Path
HOME > Browse articles > Previous issues
8 Previous issues
Filter
Filter
Article category
Keywords
Authors
Volume 39(2); June 2007
Prev issue Next issue
Original Articles
Phase II Study of Docetaxel and Cisplatin as First-line Chemotherapy in Patients with Recurrent or Metastatic Gastric Cance
Kyung-Ha Kim, Ki-Ju Jeung, Hyun-Jung Kim, Sang-Byung Bae, Chan-Kyu Kim, Nam-Su Lee, Kyu-Taek Lee, Sung-Kyu Park, Jong-Ho Won, Dae-Sik Hong, Hee-Sook Park
Cancer Res Treat. 2007;39(2):49-53.   Published online June 30, 2007
DOI: https://doi.org/10.4143/crt.2007.39.2.49
AbstractAbstract PDFPubReaderePub
Purpose

Palliative chemotherapy for patients with recurrent or metastatic gastric cancer has been shown to have a survival benefit. Docetaxel monotherapy has achieved appreciable results for treating gastric cancer. We investigated the clinical efficacy and feasibility of a docetaxel and cisplatin combination regimen for patients suffering with recurrent or metastatic gastric cancer.

Materials and Methods

Patients with histologically proven, bidimensionally measurable lesions of recurrent or metastatic gastric cancer, and they had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and no prior palliative chemotherapy were eligible for this study. The combination chemotherapy regimen consisted of docetaxel 75 mg/m2 plus cisplatin 75 mg/m2 on day 1, and this was repeated every 3 weeks until disease progression.

Results

32 patients were enrolled from 2002 to 2005. The objective response rate was 31.3% (95% confidence interval (CI): 14.2~48.2%) with no CR. The disease control rate was 59.4%. At a median follow up of 38.9 months, the median overall survival was 7.4 months (95% CI: 6.3~8.5). The median time to progression was 4.7 months (95% CI: 3.1~6.3). During a total of 106 cycles, grade 3 or 4 hematological toxicities were observed as follows: neutropenia (39 of 106 cycles) and anemia (3 of 106 cycles). The grade 3 or 4 non-hematological toxicities included anorexia (18.9%) and nausea/vomiting (21.7%).

Conclusion

Docetaxel and cisplatin combination chemotherapy showed promising anti-tumor activity and this was well tolerated as a first-line treatment for patients with recurrent or metastatic gastric cancer. Further large, randomized phase III studies are warranted.

Citations

Citations to this article as recorded by  
  • CYTOTOXIC EFFECTS OF ARIPIPRAZOLE ON MKN45 AND NIH3T3 CELL LINES AND GENOTOXIC EFFECTS ON HUMAN PERIPHERAL BLOOD LYMPHOCYTES
    Mohammad SHOKRZADEH, Abbas MOHAMMADPOUR, Mona MODANLOO, Melika HASSANI, Nasrin Ghassemi BARGHI, Parisa NIROOMAND
    Arquivos de Gastroenterologia.2019; 56(2): 155.     CrossRef
  • Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma
    Ilkay Tugba Unek, Tulay Akman, Ilhan Oztop, Olcun Umit Unal, Tarik Salman, Ugur Yilmaz
    Gastric Cancer.2013; 16(3): 428.     CrossRef
  • A randomized phase 2 study of docetaxel and S‐1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy
    Hei‐Cheul Jeung, Sun Young Rha, Chong Kun Im, Sang Joon Shin, Joong Bae Ahn, Woo Ick Yang, Jae Kyung Roh, Sung Hoon Noh, Hyun Cheol Chung
    Cancer.2011; 117(10): 2050.     CrossRef
  • Comparison of Cisplatin-5-Fluorouracil-Folinic Acid versus Modified Docetaxel-Cisplatin-5-Fluorouracil Regimens in the First-Line Treatment of Metastatic Gastric Cancer
    F. Tugba Kos, Dogan Uncu, Nuriye Özdemir, Burcin Budakoglu, Hatice Odabaş, Hüseyin Abali, Berna Oksuzoglu, Sercan Aksoy, Nurullah Zengin
    Chemotherapy.2011; 57(3): 230.     CrossRef
  • 8,669 View
  • 52 Download
  • 4 Crossref
Close layer
Autologous Stem Cell Transplantation using a Modified TAM Conditioning Regimen for Clinically Aggressive Non-Hodgkin's Lymphoma
Sook Hee Hong, Young Seon Hong, In Sook Woo, Yoon Ho Koh, Sang Young Rho, Ji Yean Peak, Myung Ah Lee, Byoung Yong Shim, Jae Ho Byun, Ji Chan Park, Jong Wook Lee, Woo Sung Min, Chun Choo Kim
Cancer Res Treat. 2007;39(2):54-60.   Published online June 30, 2007
DOI: https://doi.org/10.4143/crt.2007.39.2.54
AbstractAbstract PDFPubReaderePub
Purpose

High-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) have been used for the treatment of clinically aggressive non-Hodgkin's lymphoma (NHL). However, the superiority of specific conditioning regimens has not yet been established. The present study evaluated the efficacy and toxicity of a conditioning regimen involving fractionated total body irradiation (TBI), and the use of Ara-C and melphalan (TAM) for clinically aggressive NHL.

Materials and Methods

Between March 2002 and December 2004, 31 patients with aggressive NHL received fractionated TBI with a dose of 12 Gy over 3 days, and were administered 9 g/m2 Ara-C and 100 mg/m2 melphalan followed by autologous peripheral blood stem Cell Transplantation at the Catholic Hematopoietic Stem cell transplantation Center Korea. Patients that responded to first line chemotherapy and achieved complete remission (CR), or were in a first sensitive relapse were defined as having less advanced disease, while the other patients were defined as having more advanced disease.

Results

Objective responses were obtained in 24 of 31 patients (77.4%), comprising complete remission in 19 patients (61.3%) and partial remission in 5 (16.1%) patients. The median follow-up time was 28 months (range 1~62 months). At 3 years, the overall survival and event-free survival (EFS) rates were 62.3% and 47.3%, respectively. Patients with less advanced disease and more advanced disease showed 3-year EFS rates of 73.3% and 22.5 %, respectively (p=0.006). Early (within the first 100 days) treatment-related mortality occurred in 3 (9.7%) patients. Of the 31 total patients, 15 (48.4%) developed grade 3 mucositis, 22 (70.9%) developed neutropenic fever, and two (6.5%) developed interstitial pneumonia syndrome>grade 3.

Conclusion

The modified TAM conditioning regimen and ASCT appear to be a feasible treatment regimen for clinically aggressive NHL, particularly for patients with less advanced disease.

Citations

Citations to this article as recorded by  
  • Comparison of regional arterial chemotherapy and systemic intravenous chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis
    Chengqing Li, Wenyi Guo, Shihong Chen, Jianwei Xu, Feng Li, Lei Wang
    Journal of Pancreatology.2022; 5(2): 49.     CrossRef
  • 9,547 View
  • 55 Download
  • 1 Crossref
Close layer
Differences in Overall Survival When Colorectal Cancer Patients are Stratified into New TNM Staging Strategy
Ho-Suk Oh, Hyoung-Jung Chung, Hearn-Kook Kim, Jong-Soo Choi
Cancer Res Treat. 2007;39(2):61-64.   Published online June 30, 2007
DOI: https://doi.org/10.4143/crt.2007.39.2.61
AbstractAbstract PDFPubReaderePub
Purpose

The purpose of this study is to determine whether the prognosis can be more precisely gauged by the revised 6th AJCC staging system and if this is suitable for Korean colorectal cancer patients, and especially for those patients in the Youngdong district.

Materials and Methods

Between September 1996 and December 2003, 365 patients with histologically confirmed colorectal cancer were analyzed. Kaplan-Meier analyses were used to compare the overall and stage-specific 5-year survival. All the statistical tests were two-sided.

Results

The overall 5-year survival for the entire cohort was 62%. According to the stages defined by the AJCC fifth edition system, the 5-year stage-specific survival was 91% for stage I, 82% for stage II, 51% for stage III and 4% for stage IV. According to the stages defined by the AJCC sixth edition system, the 5-year stage-specific survival was 91% for stage I, 81% for stage IIa, 83% for stage IIb, 100% for stage IIIa, 64% for stage IIIb, 37% for stage IIIc and 4% for stage IV. The 5-year survival was significantly better for the patients with stage IIIb (64%) than those patients with stage IIIc (37%) (p<.001).

Conclusion

It is widely known that the AJCC sixth edition system for colorectal cancer stratifies survival more distinctly than does the fifth edition system by providing more substages. Our study showed that stage IIIb disease had better survival than stage IIIc disease, but we couldn't confirm that this new staging system is relevant in our Korean clinical practice due to the small study population. Therefore, further study is required in a larger population.

Citations

Citations to this article as recorded by  
  • Pathological Characteristics, Prognostic Determinants and the Outcome of Patients Diagnosed with Colorectal Adenocarcinoma at the University Teaching Hospital of Kigali
    Delphine Uwamariya, Déogratias Ruhangaza, Belson Rugwizangoga, Antonio Giovanni Solimando
    Canadian Journal of Gastroenterology and Hepatology.2022; 2022: 1.     CrossRef
  • Estimating short-term and long-term survival in rectal cancer patients using cure model
    Behrouz Beiranvand, Shaghayegh Kamian, Robabeh Ghodssi-Ghassemabadi
    Journal of Family Medicine and Primary Care.2022; 11(9): 5615.     CrossRef
  • Assessment of prognostic factors in long-term survival of male and female patients with colorectal cancer using non-mixture cure model based on the Weibull distribution
    Mehdi Azizmohammad Looha, Elaheh Zarean, Fatemeh Masaebi, Mohamad Amin Pourhoseingholi, Mohamad Reza Zali
    Surgical Oncology.2021; 38: 101562.     CrossRef
  • The role of socioeconomic disparity in colorectal cancer stage at presentation
    Aesha Patel, Owen Gantz, Pavel Zagadailov, Aziz M. Merchant
    Updates in Surgery.2019; 71(3): 523.     CrossRef
  • The effects of time valuation in cancer optimal therapies: a study of chronic myeloid leukemia
    Pedro José Gutiérrez-Diez, Miguel Ángel López-Marcos, Julia Martínez-Rodríguez, Jose Russo
    Theoretical Biology and Medical Modelling.2019;[Epub]     CrossRef
  • Permanent colostomy wound: Aeromedical disposal
    U Bhattacharya, A Kumar, AVK Raju
    Indian Journal of Aerospace Medicine.2019; 63: 39.     CrossRef
  • Analyzing the Long-Term Survival of Patients with Colorectal Cancer: A Study Using Parametric Non-Mixture Cure Rate Models
    Mehdi Azizmohammad Looha, Elaheh Zarean , Mohamad Amin Pourhoseingholi, Seyyed Vahid Hosseini, Tara Azimi, Soheila Khodakarim
    International Journal of Cancer Management.2018;[Epub]     CrossRef
  • Colorectal Cancer in Jordan: Survival Rate and Its Related Factors
    Ghazi Faisal Sharkas, Kamal H. Arqoub, Yousef S. Khader, Mohammad R. Tarawneh, Omar F. Nimri, Marwan J. Al-zaghal, Hadil S. Subih
    Journal of Oncology.2017; 2017: 1.     CrossRef
  • ROR1 expression as a biomarker for predicting prognosis in patients with colorectal cancer
    Jian-Kang Zhou, Yu-Zhu Zheng, Xue-Sha Liu, Qiheng Gou, Rui Ma, Cheng-Lin Guo, Carlo M. Croce, Lunxu Liu, Yong Peng
    Oncotarget.2017; 8(20): 32864.     CrossRef
  • High expression levels of unc-51-like kinase 1 as a predictor of poor prognosis in colorectal cancer
    YIFENG ZOU, ZEXIAN CHEN, XIAOWEN HE, XIAOSHENG HE, XIANRUI WU, YUFENG CHEN, XIAOJIAN WU, JIANPING WANG, PING LAN
    Oncology Letters.2015; 10(3): 1583.     CrossRef
  • Follow-up After Curative Resection of Colorectal Cancer
    Bridget N. Fahy
    Annals of Surgical Oncology.2014; 21(3): 738.     CrossRef
  • An overview of colorectal cancer survival rates and prognosis in Asia
    Bijan Moghimi-Dehkordi
    World Journal of Gastrointestinal Oncology.2012; 4(4): 71.     CrossRef
  • 16,694 View
  • 105 Download
  • 12 Crossref
Close layer
Clinical Characteristics of Primary Peritoneal Carcinoma
Sang Young Roh, Sook Hee Hong, Yoon Ho Ko, Tae Hee Kim, Myung Ah Lee, Byoung Yong Shim, Jae Ho Byun, In Sook Woo, Jin Hyoung Kang, Young Seon Hong, Kyung Shik Lee
Cancer Res Treat. 2007;39(2):65-68.   Published online June 30, 2007
DOI: https://doi.org/10.4143/crt.2007.39.2.65
AbstractAbstract PDFPubReaderePub
Purpose

The goal of this study was to determine the clinical and therapeutic characteristics of women with a primary peritoneal carcinoma (PPC).

Materials and Methods

A retrospective clinical study was conducted to evaluate 22 women diagnosed with a PPC from 1993 to 2007 at the Hospitals of The Catholic University of Korea. Diagnoses were based on the Gynecologic Oncology Group criteria and clinical data. We collected patient clinicopathological data including age, presenting symptoms, pretreatment CA-125 values (U/ml), clinical stage (based on the FIGO stage), performance status (using the Eastern Cooperative Oncology Group scale), whether cytoreductive surgery was optimal or not, types of chemotherapy and response to treatment. We evaluated the clinical characteristics and response to treatment, time to treatment failure and overall survival.

Results

The median overall survival of all patients was 23.1 months. The estimated 3-year survival rate was 29% (SE, 13%). The response rate to first-line platinum-based chemotherapy was 79% and the median time to treatment failure was 9.9 months (95% confidence interval, 1.38~18.4 months). By univariate and multivariate analysis, performance status was the only significant factor associated with overall survival (p<0.05).

Conclusion

We evaluated the clinical characteristics and treatment response of patients with a primary peritoneal carcinoma. Our results showed that it is possible to achieve long-term survival in patients with PPC. A further clinical study is to need to establish clinical characteristics and treatment outcomes.

Citations

Citations to this article as recorded by  
  • Incidentally Diagnosed Low-Grade Primary Peritoneal Serous Carcinoma Within the Umbilical Hernia Sac in a Male: A Report of an Extremely Rare Case and Review of the Literature
    Samer Ganam, Ayesha Khan, Nicole Riddle, Joseph A Sujka, Christopher G DuCoin
    Cureus.2024;[Epub]     CrossRef
  • Primary peritoneal high-grade serous carcinoma in a man: A case report
    Abdelali Guellil, Rachid Jabi, Mohamed Yassine Mabrouk, Laila Bouzayan, Abdelali Merhoum, Gérald Del Gallo, Claire Godart, Mohammed Bouziane
    Annals of Medicine and Surgery.2022; 77: 103605.     CrossRef
  • Primary Peritoneal Carcinoma: A Rare Malignancy Presenting a Diagnostic Challenge
    Mariam Shabbir, Sonu Sahni, Meena Ahluwalia, Raji Ayinla
    Cureus.2022;[Epub]     CrossRef
  • A case of interstitial pneumonia associated with systemic sclerosis and primary peritoneal serous carcinoma successfully treated with cyclophosphamide
    Shunichi Kawamura, Toshio Kubo, Kenji Takada, Ryota Sunami, Sachi Okawa, Yoshitaka Iwamoto, Atsuko Hirabae, Akihiko Taniguchi, Yoshinobu Maeda, Katsuyuki Kiura, Masahiro Tabata
    International Cancer Conference Journal.2021; 10(3): 197.     CrossRef
  • Primary peritoneal mucinous cystadenocarcinoma mimicking possible recurrent ovarian mucinous cystadenoma: coincidental pathology or a spectrum of disease?
    Claire Filippini, Sarah Smyth, Hooman Soleymani Majd, Catherine Johnson
    BMJ Case Reports.2021; 14(7): e242478.     CrossRef
  • Imaging features of primary peritoneal serous carcinoma: A case report
    Ji Soo Oh, Beum Jin Kim, Myoung Jin Ju, Eun Ae Yoo
    Radiology Case Reports.2020; 15(7): 978.     CrossRef
  • Unexpected primary fallopian tube carcinoma during gynecological operations: Clinicopathological and prognostic factors analyses of 67 cases
    Mingming Sun, Lingjie Bao, Haoran Shen, Min Ji, Liangqing Yao, Xiaofang Yi, Wei Jiang
    Taiwanese Journal of Obstetrics and Gynecology.2019; 58(5): 626.     CrossRef
  • Complications of Acute Pancreatitis Misdiagnosed as Primary Serous Papillary Carcinoma
    Jin Wook Lee, Eun Taek Park
    The Korean Journal of Pancreas and Biliary Tract.2018; 23(2): 54.     CrossRef
  • Inguinal Lymph Node Metastasis of a Primary Serous Papillary Carcinoma of the Peritoneum One Year after CRS and HIPEC
    Shadi Katou, Mathilde Feist, Wieland Raue, Johann Pratschke, Beate Rau, Andreas Brandl
    Visceral Medicine.2018; 34(4): 307.     CrossRef
  • Diagnostic and prognostic value of HE4 in female patients with primary peritoneal carcinoma
    Dong Mi, Yuexiang Zhang
    The International Journal of Biological Markers.2018; 33(4): 395.     CrossRef
  • Long-term survival of high-grade primary peritoneal papillary serous adenocarcinoma: a case report and literature review
    Jingping Yuan, Liang He, Bing Han, Yan Li
    World Journal of Surgical Oncology.2017;[Epub]     CrossRef
  • An unusual cancer involving the rectum: two cases of localized primary peritoneal carcinoma mimicking rectal carcinoma
    Jinnie S. Y. Pang, Liying Yang, Ghee Kheng Chew, Min Hoe Chew
    International Journal of Colorectal Disease.2016; 31(3): 717.     CrossRef
  • Primary peritoneal serous carcinoma, an extremely rare malignancy: A case report and review of the literature
    WOO-SUNG YUN, JUNG-MIN BAE
    Oncology Letters.2016; 11(6): 4063.     CrossRef
  • Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms
    Lauren Patterson Cobb, Stephanie Gaillard, Yihong Wang, Ie-Ming Shih, Angeles Alvarez Secord
    Gynecologic Oncology Research and Practice.2015;[Epub]     CrossRef
  • Amylase-Producing Primary Peritoneal Carcinoma
    Ji-Woon Lee, Sang-Gon Park
    The Korean Journal of Medicine.2015; 89(3): 358.     CrossRef
  • Solitary primary peritoneal carcinoma arising from the omentum
    Yi-Jou Tai, Ming-Chieh Lin, Chin-Jui Wu, Chi-An Chen, Wen-Fang Cheng
    Taiwanese Journal of Obstetrics and Gynecology.2014; 53(2): 256.     CrossRef
  • Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report
    Skyler B. Johnson, Joann I. Prisciandaro, Jessica Zhou, Scott W. Hadley, R. Kevin Reynolds, Shruti Jolly
    Journal of Applied Clinical Medical Physics.2014; 15(1): 202.     CrossRef
  • Embryonic natural orifice transumbilical endoscopic surgery (E-NOTES) for adnexal tumors
    Myong Cheol Lim, Tae-Joong Kim, Sokbom Kang, Duk-Soo Bae, Sang-Yoon Park, Sang-Soo Seo
    Surgical Endoscopy.2009; 23(11): 2445.     CrossRef
  • 10,174 View
  • 92 Download
  • 18 Crossref
Close layer
Detection of Lung Cancer using MAGE A1-6 and SSX4 RT-PCR Expression Profiles in the Bronchial Wash Fluid
Kwan-Ho Lee, Kyung-Chul Shin, Chae-Hun Lee, Sang-Hoon Jheon, Chang-Ho Jeon
Cancer Res Treat. 2007;39(2):69-73.   Published online June 30, 2007
DOI: https://doi.org/10.4143/crt.2007.39.2.69
AbstractAbstract PDFPubReaderePub
Purpose

Bronchial wash fluid may be a useful for detecting lung cancer. To increase the detection rates, we performed molecular analysis with using MAGE A1-6 and SSX4 RT-PCR on bronchial wash fluid specimens.

Materials and Methods

We obtained 57 lung cancer tissue specimens by bronchoscopic biopsy and 131 bronchial washes from 96 patients with lung cancer and 35 patients with benign lung diseases. The MAGE A1-6 and SSX4 gene expressions were investigated in the cancer tissue specimens and bronchial wash fluids. We evaluated the positive detection rates of these methods according to the cytology results and the clinical findings.

Results

For the cancer tissue specimens and the bronchial wash fluid, the positive detection rate of MAGE or SSX4 was 91.2% and 75.0%, respectively. Combined MAGE and SSX4 PCR and cytology tests showed an 83.3% detection rate for the bronchial wash fluid. From bronchial washes of patients with benign lung diseases, the positive rates of using MAGE or SSX4 was 11.4%. In the bronchial wash fluid of lung cancer patients, 66.7% of the peripheral cancers were detected by MAGE or SSX4, while examination with cytology did not detect any peripheral lung cancer.

Conclusion

The application of both MAGE and SSX4 showed high sensitivity and specificity for the detection of lung cancer. Thus, MAGE and SSX4 RT-PCR may be effectively utilized as additional methods to improve detection of lung cancer with using bronchial wash fluids.

Citations

Citations to this article as recorded by  
  • Characterization of Melanoma-Associated Antigen-A Genes Family Differential Expression in Non-Small-Cell Lung Cancers
    Shirin Karimi, Foroozan Mohammadi, Mihan Porabdollah, Seyed Amir Mohajerani, Kian Khodadad, Seyed Alireza Nadji
    Clinical Lung Cancer.2012; 13(3): 214.     CrossRef
  • Expression of MAGE A 1-6 and SSX 1-9 Genes in the Sputum and Cancer Tissue of the Lung Cancer Patients
    Yeun Jae Lee, Jang Hoon Lee, Jung Cheul Lee, Kwan Ho Lee
    Tuberculosis and Respiratory Diseases.2011; 70(4): 315.     CrossRef
  • 9,262 View
  • 44 Download
  • 2 Crossref
Close layer
An Attempt for Combining Microarray Data Sets by Adjusting Gene Expressions
Ki-Yeol Kim, Se Hyun Kim, Dong Hyuk Ki, Jaeheon Jeong, Ha Jin Jeong, Hei-Cheul Jeung, Hyun Cheol Chung, Sun Young Rha
Cancer Res Treat. 2007;39(2):74-81.   Published online June 30, 2007
DOI: https://doi.org/10.4143/crt.2007.39.2.74
AbstractAbstract PDFPubReaderePub
Purpose

The diverse experimental environments in microarray technology, such as the different platforms or different RNA sources, can cause biases in the analysis of multiple microarrays. These systematic effects present a substantial obstacle for the analysis of microarray data, and the resulting information may be inconsistent and unreliable. Therefore, we introduced a simple integration method for combining microaray data sets that are derived from different experimental conditions, and we expected that more reliable information can be detected from the combined data set rather than from the separated data sets.

Materials and Methods

This method is based on the distributions of the gene expression ratios among the different microarray data sets and it transforms, gene by gene, the gene expression ratios into the form of the reference data set. The efficiency of the proposed integration method was evaluated using two microarray data sets, which were derived from different RNA sources, and a newly defined measure, the mixture score.

Results

The proposed integration method intermixed the two data sets that were obtained from different RNA sources, which in turn reduced the experimental bias between the two data sets, and the mixture score increased by 24.2%. A data set combined by the proposed method preserved the inter-group relationship of the separated data sets.

Conclusion

The proposed method worked well in adjusting systematic biases, including the source effect. The ability to use an effectively integrated microarray data set yields more reliable results due to the larger sample size and this also decreases the chance of false negatives.

Citations

Citations to this article as recorded by  
  • spatiAlign: an unsupervised contrastive learning model for data integration of spatially resolved transcriptomics
    Chao Zhang, Lin Liu, Ying Zhang, Mei Li, Shuangsang Fang, Qiang Kang, Ao Chen, Xun Xu, Yong Zhang, Yuxiang Li
    GigaScience.2024;[Epub]     CrossRef
  • AMDBNorm: an approach based on distribution adjustment to eliminate batch effects of gene expression data
    Xu Zhang, Zhiqiang Ye, Jing Chen, Feng Qiao
    Briefings in Bioinformatics.2022;[Epub]     CrossRef
  • reComBat: batch-effect removal in large-scale multi-source gene-expression data integration
    Michael F Adamer, Sarah C Brüningk, Alejandro Tejada-Arranz, Fabienne Estermann, Marek Basler, Karsten Borgwardt, Thomas Lengauer
    Bioinformatics Advances.2022;[Epub]     CrossRef
  • Harmonization strategies for multicenter radiomics investigations
    R Da-Ano, D Visvikis, M Hatt
    Physics in Medicine & Biology.2020; 65(24): 24TR02.     CrossRef
  • A Novel Statistical Method to Diagnose, Quantify and Correct Batch Effects in Genomic Studies
    Gift Nyamundanda, Pawan Poudel, Yatish Patil, Anguraj Sadanandam
    Scientific Reports.2017;[Epub]     CrossRef
  • Batch effect removal methods for microarray gene expression data integration: a survey
    C. Lazar, S. Meganck, J. Taminau, D. Steenhoff, A. Coletta, C. Molter, D. Y. Weiss-Solis, R. Duque, H. Bersini, A. Nowe
    Briefings in Bioinformatics.2013; 14(4): 469.     CrossRef
  • Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells
    Hyun Chang, Sun Young Rha, Hei-Cheul Jeung, Jae-Jun Jung, Tae Soo Kim, Ho Jeong Kwon, Byung Soo Kim, Hyun Cheol Chung
    Journal of Cancer Research and Clinical Oncology.2010; 136(12): 1901.     CrossRef
  • 9,601 View
  • 69 Download
  • 7 Crossref
Close layer
The Chemopreventive Effect of Retinoids on Cellular NF-κB Activity Induced by NMU and NEU in Human Malignant Keratinocytes
Ki-Young Moon
Cancer Res Treat. 2007;39(2):82-87.   Published online June 30, 2007
DOI: https://doi.org/10.4143/crt.2007.39.2.82
AbstractAbstract PDFPubReaderePub
Purpose

Retinoids have been shown to be effective in suppressing tumor development when chemical carcinogens such as N-nitroso-N-methylurea (NMU) and N-nitroso-N-ethylurea (NEU) were used to induce mammary tumors in a variety of animal models. However, the molecular mechanisms associated with the retinoid-mediated chemopreventive process, as linked to transcription factor NF-κB activation, for chemoprevention have not been elucidated. The purpose of this study was to determine the implications of NF-κB activation on the chemopreventive role of retinoids and their effect on cellular NF-κB activity that's induced by known alkylating chemical carcinogens such as NMU and NEU in human transfectant squamous cell carcinoma (SCC-13) cells.

Materials and Methods

The activity of NF-κB, as regulated by chemical carcinogens and retinoids, was determined in cultured human SCC-13 keratinocytes that were transfected with the pNF-κB-SEAP-NPT plasmid; this permitted the expression of the secretory alkaline phosphatase (SEAP) reporter gene in response to the NF-κB activity, and the plasmid contained the neomycin phosphotransferase (NPT) gene, which confers resistance to geneticin. The reporter enzyme activity was measured using a fluorescence detection assay method.

Results

All-trans retinoic acid and 13-cis retinoic acid induced a reduction of NF-κB activity up to 64% and 65%, respectively, compared to the control. For the treatment of the human transfectant cells with chemical carcinogens, all-trans retinoic acid (5 mM) and 13-cis retinoic acid (5 mM) downregulated the cellular NF-κB activation up to 83% and 85% compared to the NF-κB activity that was upregulated by NMU (5µM) and NEU (5µM), respectively.

Conclusion

These results suggest that the chemopreventive effect of retinoids may be mediated by the downregulated activation of NF-κB and that retinoids are implicated in the activation of NF-κB in human skin cells.

Citations

Citations to this article as recorded by  
  • Upregulation of Nitric Oxide Synthase Activity by All-transRetinoic Acid and 13-cisRetinoic Acid in Human Malignant Keratinocytes
    Ki-Young Moon
    Biomedical Science Letters.2019; 25(2): 196.     CrossRef
  • N-nitroso-N-methylurea and N-nitroso-N-ethylurea Decrease in Nitric Oxide Production in Human Malignant Keratinocytes
    Ki-Young Moon
    Biomedical Science Letters.2018; 24(1): 50.     CrossRef
  • Inhibitory Effect of Retinoids on Alkaline Phosphatase Isoenzymes Activity in Human Serum
    Seung Hee Kim, Ki-Young Moon
    Biomedical Science Letters.2017; 23(3): 230.     CrossRef
  • Targeting Neuroblastoma Stem Cells with Retinoic Acid and Proteasome Inhibitor
    Barbara Hämmerle, Yania Yañez, Sarai Palanca, Adela Cañete, Deborah J. Burks, Victoria Castel, Jaime Font de Mora, Yiqun G. Shellman
    PLoS ONE.2013; 8(10): e76761.     CrossRef
  • Retinoids: novel immunomodulators and tumour‐suppressive agents?
    MR Carratù, C Marasco, G Mangialardi, A Vacca
    British Journal of Pharmacology.2012; 167(3): 483.     CrossRef
  • Acrolein, an I-κBα-independent downregulator of NF-κB activity, causes the decrease in nitric oxide production in human malignant keratinocytes
    Ki-Young Moon
    Archives of Toxicology.2011; 85(5): 499.     CrossRef
  • N-nitroso-N-methylurea and N-nitroso-N-ethylurea induce upregulation of cellular NF-κ B activity through protein kinase C-dependent pathway in human malignant keratinocytes
    Ki-Young Moon
    Archives of Pharmacal Research.2010; 33(1): 133.     CrossRef
  • 7,792 View
  • 48 Download
  • 7 Crossref
Close layer
Case Report
A Case of Organizing Pneumonia Associated with Rituximab
Chi Hoon Maeng, Sang Ouk Chin, Byung Hyuk Yang, Si-young Kim, Hwi-Joong Youn, Kyung Sam Cho, Sun Kyung Baek, Sun Lee
Cancer Res Treat. 2007;39(2):88-91.   Published online June 30, 2007
DOI: https://doi.org/10.4143/crt.2007.39.2.88
AbstractAbstract PDFPubReaderePub

Rituximab is a human/murine chimeric anti-CD20 monoclonal antibody used to treat CD20-positive B-cell non-Hodgkin's lymphoma (NHL). Although most of the adverse effects associated with rituximab are usually reversible and temporary infusion-related reactions, including fever, chills, flushing and skin reactions, there are several reports of pulmonary events after long-term administration of rituximab. We present a case of asymptomatic nodular organizing pneumonia occurring during rituximab-based chemotherapy in a patient with non-Hodgkin's lymphoma.

Citations

Citations to this article as recorded by  
  • Rituximab for steroid-resistant organising pneumonia in a woman with rheumatoid arthritis
    Christine Elizabeth Loftis, Emilia Dulgheru, Adolfo Kaplan
    BMJ Case Reports.2022; 15(11): e249912.     CrossRef
  • Organizing pneumonia associated with T‐cell lymphoma
    Chrystal Chan, Andrei D. Fagarasanu, Andre Reid, Daniel C. Sadowski, Ashley‐Mae E. Gillson
    Respirology Case Reports.2020;[Epub]     CrossRef
  • Non-infectious pulmonary toxicity of rituximab: a systematic review
    A. V. Hadjinicolaou, M. K. Nisar, H. Parfrey, E. R. Chilvers, A. J. K. Ostor
    Rheumatology.2012; 51(4): 653.     CrossRef
  • Toxic Epidermal Necrolysis after Rituximab Therapy for Immune Thrombocytopenic Purpura
    Soo-Young Bae, Yeo-Kyeoung Kim, Joo-Young Yoon, Sung-Ji Lee, Dae Eun Kim, Sung Yoon Rew, Seung Dok Hong, Dae-Ho Jo, Joon-Il Hwang, Woo-Kyun Bae, Hyun-Jeong Shim, Jae-Sook Ahn, Deok-Hwan Yang, Sang-Hee Cho, Je-Jung Lee, Ik-Joo Chung, Hyeoung-Joon Kim
    The Korean Journal of Hematology.2009; 44(2): 108.     CrossRef
  • 8,735 View
  • 82 Download
  • 4 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP